HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ischemic colitis during treatment with alosetron.

Abstract
Irritable bowel syndrome (IBS) is one of the most common entities observed by both primary care physicians and gastroenterologists. Alosetron is a potent and selective serotonin antagonist that recently became the first Food and Drug Administration-approved agent for diarrhea-predominant IBS. However, since approval, significant side effects have been noted with the use of alosetron including severe constipation, fecal impaction, and ischemic colitis. We describe a case of ischemic colitis in a male patient with IBS who was briefly treated with alosetron. Clinical, endoscopic, and pathologic features of the focal colitis strongly suggested ischemia. Symptoms correlated temporally with alosetron use, and symptoms abated with discontinuation of the drug. Endoscopic and pathologic resolution of the colitis were documented.
AuthorsD Friedel, R Thomas, R S Fisher
JournalGastroenterology (Gastroenterology) Vol. 120 Issue 2 Pg. 557-60 (Feb 2001) ISSN: 0016-5085 [Print] United States
PMID11159896 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Carbolines
  • Serotonin Antagonists
  • alosetron
Topics
  • Carbolines (adverse effects)
  • Colitis (chemically induced, pathology)
  • Colonic Diseases, Functional (drug therapy, pathology)
  • Colonoscopy
  • Humans
  • Ischemia (chemically induced, pathology)
  • Male
  • Middle Aged
  • Serotonin Antagonists (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: